Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05556863 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers
A Phase 1 study, sponsored by Electra Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT05556863 is a Phase 1 study that has completed, run by Electra Therapeutics. The registered enrollment target is 91 participants.
The verdict
NCT05556863, a Phase 1 study, has completed, sponsored by Electra Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Adults.
Interventions
- DRUG ELA026
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2023-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05556863
The ClinicalTrials.gov registry entry for NCT05556863 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Electra Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ELA026 is the first listed.
NCT05556863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05556863 about?
NCT05556863 is a clinical study titled "Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers". ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Adults.
What is the current status of trial NCT05556863?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2021-10-18. Estimated completion is 2023-11-20.
What interventions are being tested in trial NCT05556863?
The interventions under investigation include: ELA026 (DRUG).
Who is sponsoring clinical trial NCT05556863?
This trial is sponsored by Electra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.